A recent COVID-19 variant, designated as a “variant of interest” by the World Health Organization (WHO), has stirred concerns in India, though it’s reassured that it doesn’t pose a significant threat to public health. Known as the JN.1 variant, it originated in Luxembourg and is a descendant of the Pirola variant (BA.2.86), which traces its roots back to the Omicron sub-variant.
This variant has contributed to a rise in active COVID-19 cases in India, reaching 1,828 on Monday, December 18, with one reported death in Kerala, where JN.1 was recently identified. In response, the central government has issued advisories to state governments, urging them to ensure adequate health arrangements.
As per the WHO, symptoms linked to the JN.1 variant are generally mild to moderate, including a loss of appetite and persistent nausea. Sudden difficulty feeling hungry, especially when accompanied by other symptoms, is highlighted as a potential indicator, warranting medical consultation.
Extreme fatigue is another significant sign of the JN.1 variant, characterized by overwhelming exhaustion and muscle weakness that goes beyond typical COVID-19 fatigue. Individuals experiencing such fatigue are advised to seek medical evaluation.
In rare cases, those infected with the JN.1 variant may also encounter gastrointestinal problems, leading to changes in digestive health, such as vomiting and nausea.
The CDC suggests that the surge in cases indicates JN.1 may be more transmissible compared to other strains. Concerns arise due to a combination of factors, including holiday gatherings, low COVID-19 vaccine rates, and the presence of a new, transmissible variant. Health experts emphasize the importance of wearing masks in crowded places to mitigate risks.
Currently, over 90% of COVID cases in India are mild and managed through home isolation.